Details for Patent: 12,161,653

« Back to Dashboard

Which drugs does patent 12,161,653 protect, and when does it expire?

Patent 12,161,653 protects KYBELLA and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 12,161,653

Title:	Treatment of submental fat
Abstract:	This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
Inventor(s):	Patricia Walker
Assignee:	Allergan Sales LLC
Application Number:	US17/752,056
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,161,653

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	12,161,653					IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING

International Family Members for US Patent 12,161,653

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2827643
European Patent Office	2675460
Mexico	2013009559